Imatinib Mesylate in Treating Patients With Gliomas
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth
of the tumor.
PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients
who have gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC